At first glance, it doesn't look like a pretty chart. But, look closer.
On multiple occasions over the previous 6 months, BNOX has gone on killer intraday rips of a $1.00+. Here's a few examples (runs from open to high of day):
#1. 10/27/22 - $1.50 intraday
#2. 11/4/22 - $1.48 intraday
#3. 11/9/22 - $1.96 intraday
#4. 1/26/23 - $1.60 intraday
And in the past few days alone...
BNOX surged from a $3.31 open to a $7.71 high Tuesday for a 132% intraday run.
Now, are we saying BNOX will make that same type of move Thursday?
No. Nothing is certain. But, it is important to take note of this profile's chart history and low float (under 6Mn shares).
No. 3 BNOX Potential Catalyst - New President/CEO Is Critical Milestone For The Leadership Team
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
Experienced biotech executive to lead the next phase of growth
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer (CEO), effective 5 January 2023. ...
Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders. He held various positions of increasing responsibility at CNS-focused start-up/small, medium specialty and large biopharma companies. Since 2020, he has been the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq-listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Spyros has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Spyros received his MD and PhD in Greece from the University of Patras, School of Medicine and before joining the biopharmaceutical industry served as faculty at the Department of Neurology of the University of Miami, School of Medicine.
Dr. De Souza commented, “Bionomics is at a key inflection point in its development and potential transition from an early-stage development organization to a later stage clinical development and commercial organization as we await the data from our two ongoing Phase 2 clinical trials of BNC210 for the acute treatment of social anxiety disorder and chronic treatment of post-traumatic stress disorder by year end 2022 and mid-2023, respectively. Having led the Company turn around over the past three years, I am delighted to hand over the reins to Spyros to leverage his extensive experience in leading R&D and commercial organizations in both the private and public sector and small biotech and large pharmaceutical companies to continue to progress the pipeline and in doing so, build value for patients and shareholders. I will continue to be closely involved with Bionomics in my oversight role as Non-Executive Chairman of the Board.”
Dr. Papapetropoulos added, “I am delighted to be joining Bionomics as President, CEO and Director and building upon the great strides the Company has made under Errol’s leadership. The psychiatric and neurological disorders which Bionomics is targeting represent large, unsolved medical challenges for which patients need new options. I look forward to working with the Board, the management team and Bionomics employees in leading the Company as we prepare for its next stage of growth.”
Read the full article here.
No. 4 BNOX Potential Catalyst - Could Momentum Be Building? BNOX Closes Wednesday Above Key Lines Of Potential Support
Let's go back to BNOX's 6-month chart real quick.
I've highlighted a handful of key lines of potential support to pay close attention to in the link above.
First off, BNOX is currently trading above these key lines of potential support:
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
- 50-Day Simple Moving Average (SMA)
But here's the one to pay close attention to right now since it was tested this week: its 200-Day SMA.
On Tuesday, BNOX, trading above those 3 key lines mentioned above, ran all the way up to its 200-Day SMA before being promptly turned away.
As you can see, there is a ton of potential room to move from its current trading levels to what may be its next line of potential resistance in its 200-Day SMA.
If potential support continues to grow at those 3 key levels I mentioned above, it could slowly become the foundation to allow BNOX to try and test that 200-Day SMA resistance again in the near term.
And if that happens, it would obviously be a significant move from current trading levels.
On top of that, StockTA.com is reporting a very bullish EMA situation for BNOX.
The site shares that not only is BNOX trading above both its 5-Day and 13-Day EMA's, its 5-Day EMA is also trading above its 13-Day EMA in very bullish manner.
Make sure to keep an eye on all these lines moving forward.
BNOX Recap - These Potential Catalysts Could Provide A Major Breakout Spark
No. 1 - Low Float Could Provide Significant Volatility Potential On Daily Basis
No. 2 - An Explosive Chart History With Several Massive Intraday Rips
No. 3 - New President/CEO Is Critical Milestone For The Leadership Team
No. 4 - Could Momentum Be Building? BNOX Closes Wednesday Above Key Lines Of Potential Support
Coverage is officially initiated on BNOX. When time permits, do this: